Kumukuai Peptide & Ka hiki 2026: Thermo Fisher & Nā Haʻawina GenScript

Pane wikiwiki

Strategic analysis of Thermo Fisher and GenScript 2026 hopena: ka laka aelike peptide lehulehu, reagent lead times, and boutique CDMO selection.

Heluhelu ʻia nā loaʻa macro: Wehewehewehe 2026 Ke kumu kūʻai o ka lawelawe Peptide a me nā hōʻailona kaha

E hoʻomaopopo i kēia manawa ke kumu kūʻai a me ka hiki ke lawelawe peptide 2026 dynamics, Pono nā mea hoʻoholo biopharma e nānā pono i ke ʻano o ka hoʻokaʻawale ʻana o nā lako ʻepekema ola nui a me nā mea hoʻolako synthesis i ke kapikala a me nā kumuwaiwai hana..

Kumukuai Peptide & Ka hiki 2026: Thermo Fisher & Nā Haʻawina GenScript

Thermo Fisher Scientific: Ka Paʻa Paʻa a me ka Mana Bioprocessing

Wahi a ʻO Thermo Fisher 2025 nā hopena makahiki, loaʻa ka loaʻa kālā piha makahiki $44.56 piliona (i luna 4% makahiki-i-makahiki), me ka hāhā-hāhā ka loaʻa kālā $12.21 piliona (i luna 7%). Ke nānā nei i mua 2026, alakaʻi alakaʻi hoʻokele waiwai ulu ulu o 4% i 6% ($46.3 piliona i $47.2 piliona), e hōʻike ana i ka hoʻokūpaʻa ākea ākea ma waena o nā huahana laboratory a me nā reagents bioprocessing.

ʻO ka pālākiō Thermo Fisher e hōʻoiaʻiʻo i ka hilinaʻi like ʻole no nā mea hana synthesis off-the-shelf, nā mea hoʻohui maʻamau, a me nā mea hoʻopau helu helu. Eia naʻe, Ke kākoʻo mau nei kāna mea nui i ka hoʻonohonoho ʻana i nā mea kūʻai aku biomanufacturing pāʻoihana a me nā kahe hana bioprocessing kiʻekiʻe.. No nā hui hoʻomohala biopharma e noi ana i nā kaʻina hana maʻamau a i ʻole nā ​​pūʻulu pailaka liʻiliʻi a waena, ʻO ka hoʻokele ʻana i kahi ʻoihana multi-billion-dollar e hoʻolauna pinepine i ka inertia hoʻokele a me ka paʻa, nā pae lawelawe maʻamau ma mua o ka loiloi synthesis i hoʻohālikelike ʻia.

Kumukuai Peptide & Ka hiki 2026: Thermo Fisher & Nā Haʻawina GenScript

ʻO GenScript Biotech: Hoʻokomo ʻakomi vs. Nā Paʻa Kūʻai Kūʻai

He ʻokoʻa, ʻO ka hōʻike hana makahiki FY2025 a GenScript hōʻike i ka piʻi ʻana o ka loaʻa kālā o ka hui 61.4% i $959.5 miliona, me ka loaʻa kālā i hoʻoponopono ʻia ʻaneʻane pākolu $230.3 miliona. ʻO kāna pūʻulu ola ʻepekema kumu (LSG) hana ʻia $522.1 miliona (i luna 14.8% YoY), alakaʻi maopopo ʻia e ka piʻi ʻana o ka ulu ʻana o ka gene automated a me ka synthesis peptide high-throughput.

Ua hoʻohaʻahaʻa maikaʻi ka hoʻonui ʻana o GenScript i nā puka makani no ka maʻamau, nā kaʻina noiʻi haʻahaʻa paʻakikī a hiki i ka wikiwiki 5 lā. Eia naʻe, e like me ka palapala ma ʻO Q2 o nā limahana Peptide 2026 ʻikepili kumu kūʻai ʻaelike, Ua ʻike nā tier-1 mega-CDMO i ka lele ʻana o ke kumu kūʻai aelike GLP-1 API 25% i 40% mai 2023. ʻOiai ʻoi aku ka maikaʻi o nā paepae automated i nā peptides linear maʻamau, paʻakikī multi-disulfide cyclization, lipidation, a me ka maemae loa (>98%) Pono nā kauoha maʻamau i ka hoʻomaʻemaʻe manual kūikawā a me ka mālama ʻana i ka lumi hoʻomaʻemaʻe ʻaʻole i hoʻonohonoho ʻia nā laina catalog automated e hana mua..

Waiwai & Metric hana

Thermo Fisher Scientific

ʻO GenScript Biotech (Pūʻulu ʻepekema Ola)

FY2025 Loaʻa Hoʻohui

$44.56 Piliona (+4% YoY)

$959.5 Miliona (+61.4% YoY)

ʻIke Ola / Loaʻa ka ʻāpana LSG

Nā Huahana Laba Nui & Nā lawelawe

$522.1 Miliona (+14.8% YoY)

Ka Manaʻo Hoʻohana Nui

ʻoihana bioprocessing & nā mea hoʻopaʻa inoa

Gene kiʻekiʻe hoʻohana ʻokoʻa & peptide synthesis

Hiki ke huli

Nā manawa alakaʻi papa inoa maʻamau

Hōʻike i ka lawe ʻana i nā lā 5 no nā kaʻina maʻamau

Nā Manaʻo Kūʻai

Paʻa lako hohonu; paakiki R&D hoʻopilikino

ʻO ka wikiwiki kiʻekiʻe no ka hana maʻalahi; pilikia ka laina no nā kaʻina paʻakikī

Ka Manaʻo ʻOihana: "ʻO ka pilikia mua e kū nei 2026 ʻAʻole koi ke kūʻai ʻana o biopharma i ka maopopo ʻole - ʻo ia ka hoʻokaʻawale ʻana,” wahi a Dr. Elena Vance, Luna Hoʻokele Koʻikoʻi o Sourcing Strategy ma BioPharma Supply Insights. "Ke hoʻomau nei nā ʻaelike GLP-1 kalepa i nā laina bioprocessing tier-1 CDMO a me nā slot lumi maʻemaʻe.. No nā papahana peptide maʻamau a paʻakikī, ʻO ka hilinaʻi nui ʻana i nā mea hoʻolako mega e hoʻolauna i nā pilikia koʻikoʻi i ka wā alakaʻi, ka hana ʻana i ka hōʻailona CDMO lua a me nā hui kūʻai agile e pono ai no ka hoʻomau mau ʻana.


Ka Reagent Lead-Time Risk: Hōʻike ʻia nā mea maka ma luna o ka hana ʻana i ka Peptide

ʻO kahi haʻahaʻa koʻikoʻi i ka kūʻai ʻana i ka peptide maʻamau e waiho ana ma luna o ka papa reagent kemika. Wahi a kahi mea hou ka nānā ʻana i nā kumu kūʻai maka, nā ʻakika amino kūikawā, hale kūkulu ʻokoʻa, a me nā mea hoʻohui hou (e like me HATU, PyBOP, a me PyAOP) mooolelo no 60% i 70% o ka huina o na koina hana peptide.

Hoʻohuihui Peptide I ka loiloi ʻana i nā ʻōlelo a ka mea hoʻolako, R&Pono nā hui D e hoʻomaopopo i nā manawa alakaʻi reagent e kuhikuhi pololei i nā papa hoʻolaha papahana. ʻo kahi laʻana:

  • ʻO Resin a me nā hui pale: Ua hoʻopaʻa ʻia ka resin Rink Amide MBHA pāʻoihana ma kahi o $180-$230/kg. Eia naʻe, pharmaceutical grade, ʻO ka resin endotoxin haʻahaʻa i koi ʻia no nā haʻawina hoʻonaʻauao IND e lawe i kahi kumu kūʻai kumu kūʻai 2x-3x a koi aku i ka hōʻoia mea kūʻai aku..

  • Kūlohelohe & Nā ʻakika Amino i hoʻololi ʻia: Nā ʻakika D-amino, N-methylated koena, a me nā poloka hale fluorinated e hilinaʻi pinepine i nā mea hoʻolako kemika kūloko kūikawā. Inā ʻaʻole mālama ka CDMO i nā lāʻau palekana ikaika, hiki ke hoʻohui i nā manawa alakaʻi kūʻai no nā poloka hale kakaʻikahi 8 i 16 nā pule i kahi papa manawa synthesis.

  • Mea hoʻoheheʻe & lumi hoʻomaʻemaʻe ma luna: ʻO ka peptide synthesis paʻa (SPSS) hoʻopuka i ka nui o ka solvent (DMF, DCM, NMP). Paʻa ka hoʻokō kaiapuni i ka honua holoʻokoʻa, ke koi ʻana i nā mea hoʻolako papa-1 e hoʻopau i ka holo ʻana o ka hana i ka wā e hiki ai i ka hoʻoheheʻe hou ʻana a i ʻole nā ​​​​mea hana ʻōpala.

⚠️ ʻŌlelo Aʻo: Mai noʻonoʻo i kahi ʻōlelo CDMO i hoʻokumu wale ʻia ma ke kumu kūʻai pākahi-gram. ʻO kahi kumu kūʻai haʻahaʻa haʻahaʻa i nele i ka waiwai reagent i hōʻoia ʻia a hilinaʻi paha i nā poloka kūkulu hale kūʻai wahi i hoʻopaʻa ʻole ʻia e alakaʻi pinepine i nā lohi mau mahina a me nā pōʻino hōʻole i ka wā hoʻomaʻemaʻe..


Hoʻolālā Laka ʻaelike: ʻO ka manawa a pehea e kūkulu ai i nā ʻaelike Peptide Nui

Hāʻawi ʻia i ka ʻokoʻa ma waena o ka loaʻa ʻana o ka catalog a me ka hiki maʻamau, Pono nā luna kūʻai biopharma e hoʻohana i nā ala hoʻolālā ka laka aelike peptide lehulehu. ʻO ka hoʻopaʻa ʻana i ka hiki ke pale i nā hale hana i ka wā e hoʻololi ai mai ka ʻike mua ʻana i ka hoʻomohala lāʻau lapaʻau.

ʻIke ʻIke (1-5 mg) → Hoʻoponopono alakaʻi (10-100 g) → IND-Hoʻā / Pilota (100 g – 1 kg)

• Nā Kūʻai Kākoʻo Spot • Laka Puʻupuʻu Nui i hoʻolaʻa ʻia

• Huli Ho'ololi wikiwiki • Ka Papa helu kumu waiwai kumu 100 Hōʻoiaʻiʻo lumi hoʻomaʻemaʻe

I ka wā e laka ai i nā ʻaelike he nui

  1. Ke komo nei i ka Lead Optimization: I ka wa e pono ai ka moho paipu 5 i 20 nā ʻano ʻokoʻa ma waena o nā pōʻai hoʻāʻo iterative he nui (10g a hiki i ka 100g hua nui), laka ana i ka 6-a-12 mahina multi-batch master service aelike (MSA) hoʻopaʻa i ka mea nui o ka synthesizer slot.

  2. E hoohana ana i na Poloka Hale Kumukuai Kiekie: Inā hoʻokomo kāu kaʻina i nā waikawa amino kūlohelohe a i ʻole nā ​​hoʻololi paʻakikī (e.g., nā peptides i hoʻopaʻa ʻia a i ʻole nā ​​lima bioconjugation), hiki i ka mea hoʻolako ke kūʻai i nā mea maka ma ka nui, laka ana i na hoemi maka.

  3. Hoʻomākaukau no nā haʻawina IND-Enabling: Pono nā polokalamu e holomua ana i ka toxicology pre-clinical i ka paʻa paʻa ʻana o ka hui (maʻemaʻe ≥98%, endotoxin <10 EU/mg). ʻO ka hoʻopaʻa ʻana i nā ʻaelike multi-batch e hōʻoiaʻiʻo ʻia ua synthesized nā ʻāpana āpau me ka hoʻohana ʻana i nā pūʻulu resin like a me nā ʻāpana hoʻomaʻemaʻe..

Nā Pauku Kuikahi Pono e hookomo

  • Nā Papa Hoʻouna Kūʻē: E wehewehe i nā lā hoʻouna ʻōwili (e.g., Pūʻulu 1 i ka pule 4, Pūʻulu 2 i ka pule 8) ma mua o ka manaʻo i ka hoʻokō hoʻokahi-nui, e ʻae ana i nā hoʻokolohua in vitro e hoʻomau me ke kali ʻole no ka hoʻopau ʻana o ka hoʻolaha.

  • Ka Papahana Kumukuai Maka: E hoʻopaʻa pono i nā hoʻololi kumu kūʻai i kākau ʻia i nā hoʻololi kumu kūʻai maka, ka pale ʻana i kāu kālā e kūʻē i nā markup margin CDMO.

  • Hōʻoiaʻiʻo Analytical & Nā Koina Hoʻokuʻu: E kauoha i ka ʻae ʻia ʻana o ka ʻāpana hope e pili ana i ka ʻikepili analytical i hōʻoia ʻia—ʻo ia hoʻi nā chromatograms HPLC, LC-MS nuipaʻa kikoʻī, a me nā palapala CoA haʻahaʻa-endotoxin—ma mua o ka hoʻoholo ʻana i ka invoice hope.


ʻEkolu-Aʻoaʻo Kūʻai Kūʻai: In-House SPPS vs. Mea hoʻolako Mega vs. Nā CDMO Buke Kūikawā

ʻO ke koho ʻana i ke kahua hana kūpono e pono ai ke kaulike ʻana i ka paʻakikī o ka kaʻina, nā pahuhopu maʻemaʻe, a me ka agility hui. Pono nā mea hoʻoholo Biopharma e loiloi i ʻekolu mau kumu hoʻokō mua:

• Ka ho'āʻo hoʻāʻo hikiwawe • Kiʻekiʻe-volume gene/peptide • Papa 100 lumi hoʻomaʻemaʻe

Hoʻohui ʻia SPPS i loko o ka hale • AA laina pōkole pōkole • Maʻemaʻe haʻahaʻa (<85%)

Pono ke kūʻai ʻana o Peptide i nā mea kūʻai aku me Mega CDMO (Thermo/GenScript) (e.g., MOL Changes) ʻO nā Peptides Synthetic • Nā hale waihona puke maʻamau • ʻO ka maʻemaʻe kiʻekiʻe ≥98% • Nā mea hoʻoheheʻe helu • 300+ hoʻololi

1. Hoʻohui ʻia SPPS i loko o ka hale

Ka mālama ʻana i nā synthesizer automated benchtop (e.g., SPPS kōkua i ka microwave) hāʻawi i nā hui kemika kūloko i ka mana piha ma luna o ka ʻimi kaʻina hana mua.

  • Kūpono ʻia no: Hoʻopaʻa wikiwiki i ka pōkole, peptides laina (<15 nā ʻakika amino) ma nā unahi milligram kahi maʻemaʻe e pono ai (<85%).

  • Nā palena: ʻO ka synthesis i loko o ka hale e lilo i mea waiwai ʻole no ka maʻemaʻe kiʻekiʻe (>95%) a i ʻole ka hana pākēneka. Hoʻomaʻemaʻe HPLC hoʻomākaukau, hoʻopili kolamu, ʻO ka hōʻoia ʻana o ke ʻano LC-MS, a ʻoi aku ka wikiwiki o ka hoʻokuʻu ʻana i ka solvent ma mua o ke kumu kūʻai o waho.

2. Mea Hoʻolako Mega Catalog (e.g., Thermo Fisher, GenScript)

ʻOi aku ka maikaʻi o nā mea hoʻolako mega i ka synthesis automated high-throughput, hāʻawi i nā koho papa inoa nui a me nā pūnaewele logistic honua.

  • Kūpono ʻia no: Kūlana, peptides noiʻi hoʻololi ʻole ʻia, hale waihona palapala palapala epitope kiʻekiʻe, a me nā mea hoʻopaneʻe hōʻike i waho o ka papa.

  • Nā palena: Hoʻohana pinepine ʻia ka kamaʻilio ma o nā ʻōnaehana tiketi portal ma mua o ke komo pololei ʻana i nā chemists synthesis. Nā hoʻololi maʻamau, nā kaʻina kaulahao lōʻihi (>30 AAs), a ʻaʻole hoʻopaʻa maʻamau ke alo i nā koi kauoha liʻiliʻi loa a me nā manawa laina lōʻihi.

3. Nā CDMO Buke Kūikawā (e.g., MOL Changes)

Noho nā mea hoʻolako kūikawā ma waena o nā synthesizer benchtop a me nā keʻena bioprocessing mega-volume, hāʻawi ʻana i ka hana ʻenehana kiʻekiʻe a me ka hāʻawi agile.

  • Kūpono ʻia no: Nā kaʻina maʻamau maʻemaʻe kiʻekiʻe (≥95–98%+), hoʻololi hoʻololi paʻakikī (>300 nā koho hui hana, me ka cyclic, hoʻopaʻa ʻia, a me nā peptides lipidated), a me ka hana ʻana i ka pae lapaʻau sterile.

  • Nā mea ʻokoʻa koʻikoʻi: E like me ka mea i hoikeia ma 2026 peptide budgeting benchmarks, nā kaʻina hoʻomaʻemaʻe kiʻekiʻe e kauoha i ke kumu kūʻai uku ($17– $32 no ka waikawa amino). Hoʻolālā nā CDMO kūikawā i kēia mau kumukūʻai ma ka hāʻawi ʻana i ka hoʻokele papahana ʻepekema-a-ʻepekema, hui pū ʻia nā ala SPPS a me ka microbial fermentation ala, a me nā suite hana hoʻolaʻa.

No nā hui e koi ana i ka mana sterile uncompromising, ka launa pū ʻana me kahi mea hoʻolako loea e like me MOL Changes hōʻoia i ke komo i sterile cleanroom manufacturing hiki hana ʻia ma lalo o ka Papa 100 kūlana hoʻomaʻemaʻe ultra. Hoʻopau kēia i ka microparticle a me ka hopena contamination endotoxin ma mua o ka hoʻopaʻa ʻana i ke kelepona a i ʻole i loko o nā haʻawina vivo.

Helu Loiloi

Ka Hoʻohui Hale

Mea Hoʻolako Mega (Thermo / GenScript)

CDMO Kūikawā Kūikawā (e.g., MOL Changes)

Pālākiō ʻoi loa

1 mg – 50 mg

1 mg – 500 g (Heluhelu / Hale Waihona Puke)

50 mg – Nui-Kilogram (ʻO R&D iā CDMO)

Māmā

Crude i 85% (Hoomaemae ole)

Kūlana 85% – 95%

Hōʻoia ≥95% i 98%+ (HPLC/MS i hōʻoia ʻia)

Hohonu Hoololi

Nā hōʻailona kumu N/C-terminal

ʻO ka fluorescent maʻamau & nā hōʻailona biotin

300+ nā hoʻololi kiʻekiʻe (Cyclic, KAUKA, Lipid)

Maʻemaʻe maʻamau

Paena hale hana maʻamau

ʻO ka pahu ʻoihana maʻamau

Papa 100 nā lumi hoʻomaʻemaʻe ultra-sterile

Kākoʻo ʻenehana

Nā limahana kemika kūloko

ʻO nā tiketi puka / Nā luna moʻokāki

Kūkākūkā pololei ʻo Scientist-to-Scientist

Ka manawa o waena o ka hoʻomaka a i ka wā pau (Kuʻuna) Hana ʻia ʻo Peptide

1–3 lā (inā nā reagents i ka waihona)

2–6 pule (Pili ka pila)

1–3 pule (ʻO ka papa hana maʻalahi)

No ke kōkua: I ka loiloi ʻana i nā CDMO boutique, e hōʻoia i ka hāʻawi ʻana o ka mea kūʻai aku i nā chromatograms HPLC maka a me nā spectrometry lehulehu (MS) profiles no kēlā me kēia ʻāpana, ʻaʻole i hōʻuluʻulu ʻia i nā palapala palapala hōʻoia o ka nānā ʻana. ʻO ka ʻikepili analytical māmā ka hōʻike maikaʻi loa o ka maikaʻi synthesis.


Nīnau pinepine (FAQ)

Pehea 2026 Hoʻopili nā hopena mea hoʻolako macro i nā manawa alakaʻi peptide synthesis maʻamau?

Hōʻike nā hopena kālā ikaika i nā mea hoʻolako mega i ka hoʻonui ʻana i ka bioprocessing a me ka nui o ka synthesis gene automated.. Eia naʻe, no ka mea, ua komo nā ʻaelike GLP-1 pāʻoihana i ka mana bioprocessing nui, kuʻuna R&ʻIke pinepine nā pūʻulu D ma nā mea hoʻolako nui i ka lohi o ka pila. Hāʻawi nā CDMO kūikawā i ka huli wikiwiki ʻana ma o ka hoʻokaʻawale ʻana i nā slot synthesis i hoʻolaʻa ʻia no R&Nā polokalamu D.

No ke aha e helu ai nā mea maka 60% i 70% o nā koina hana peptide maʻamau?

Pono ka peptide synthesis i nā waikawa amino Fmoc maʻemaʻe kiʻekiʻe, pūʻulu pale kūikawā, a me nā mea hoʻohui hoʻohui wai (e.g., KA HANAU, PyBOP). No nā kaʻina paʻakikī a hoʻololi paha, ʻO ke kumukūʻai o nā waikawa amino kūlohelohe ʻole a me nā resins kūikawā i hoʻomalu i ka bila o nā mea, ka hoʻolilo ʻana i ka waiwai maka i luna i mea hoʻokele koʻikoʻi o ka huina kumu kūʻai o ka papahana.

I ka manawa hea e hoʻololi ai kahi hui biopharma mai kahi mega-supplier catalog i kahi CDMO boutique kūikawā?

E hoʻololi i kahi CDMO kūikawā inā makemake kāu polokalamu i nā pae maʻemaʻe o ≥95% a 98%+, nā hoʻololi maʻamau ʻole (e like me ka cyclization, lipidation, a i ʻole ka hōʻailona isotope), Papa 100 hoʻopaʻa kino, a i ʻole nā ​​hoʻolālā hoʻolaha pāʻoihana lehulehu ʻaʻole hiki i nā mea hoʻolako waihona ke hoʻokipa.

He aha nā palapala maikaʻi e kauoha ʻia i nā ʻaelike peptide multi-batch?

Pono nā ʻaelike e kauoha i nā chromatograms maʻemaʻe HPLC kikoʻī, LC-MS hōʻoia lehulehu, maʻiʻo peptide net (NPC) kālailai, ka hoʻāʻo ʻana i ka moisture/solvates, a me nā hoʻokolohua endotoxin (maʻamau <10 EU/mg no ka noiʻi a <0.5 EU/mg no ka hoʻomākaukau sterile/in vivo).


Nā ʻanuʻu aʻe no ka hoʻonui ʻana i kāu 2026 Paipai Hoʻolako Peptide

Hoʻokele Thermo Fisher GenScript peptide synthesis hopena a me nā neʻe ʻana o ka mākeke macro e pono ai ke kumu hoʻohālike kūʻai kaulike. ʻOiai e mau ana ka waiwai o nā mea hoʻolako mega no nā mea kikoʻī maʻamau a me nā waihona kānana kiʻekiʻe, kūikawā R&Ke koi nei nā pipeline D i nā hoa hana agile hiki ke hoʻopuka i ka maʻemaʻe kiʻekiʻe, nā kaʻina paʻakikī me ka lohi ʻole o ka pila lōʻihi.

No ka pale ʻana i kāu pipeline mai ka reagent lead-time volatility a me nā bottlenecks hiki:

  1. Hoʻoponopono i kāu Portfolio Sequence o kēia manawa: E hoʻokaʻawale i nā peptides screening linear maʻalahi mai ka maʻemaʻe kiʻekiʻe, nā moho paʻakikī.

  2. E hoʻokumu i nā ʻaelike lawelawe kumu nui: Laka i 6-a-12 mahina hoʻopaʻa ʻia no nā moho alakaʻi no ka hoʻopaʻa ʻana i ke kumu kūʻai kumu a me ka loaʻa synthesizer..

  3. Hoʻopili i nā hoa hana loea kūikawā: E hana pololei me nā hui synthesis akamai e hoʻopaʻa pono i ka hoʻohui ʻana i ka kemika a me ka hoʻomaʻemaʻe ʻana i ka hoʻomaka ʻana o ka hoʻomohala ʻana.

No ke kākoʻo ʻenehana i hana ʻia, ka hoʻokō ʻana i nā ʻāpana he nui, a Papa 100 hana ʻino, makaikai nā hoʻonā peptide CRO a me CDMO me ka hui kemika ma MOL Changes.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana